Dupuytren’s Disease Market Size, Share & Trends Analysis Report By Disease Type (Type I, Type II, Type III), By Type (Diagnosis and Treatment), By End-user, By Region, And Segment Forecasts, 2023 To 2030

Dupuytren's disease, also known as dupuytren's, contractures, is the condition resulting in the disorder that causes the tissue in the palm to shorten and thicken, giving the fingers an impression of being clawed. It is a non-painful disease that prevents the affected fingers from fully straightening by causing one or more of them to bend inward towards the hand's palm. The palmar fascia slowly thickens and eventually constricts in those with Dupuytren's disease. It mostly affects the little and middle fingers. Increasing geriatric population across the globe is the major factor increasing the risk of developing this medical condition. It is mostly observed in the male population over age 50+.

Possible risk factors causing the palmar fascia to thicken and contract includes the exposure to manual labor vibration, past hand injuries, smoking, hyperlipidemia, Peyronie disease, and complicated regional pain syndrome (CRPS). Other factors such as age & gender, ancestral history of Scandinavian DNA ancestry, people with diabetes & epilepsy, alcohol consumption, and smoking are the causes of the disorder.

The increasing prevalence of diabetes, growing older population, advances in medical technology, expanding awareness programs by public & private organizations, and government supports are the major drivers for Dupuytren's disorder market growth. Moreover, key market players involved in strategic agreements and collaborations for product portfolio expansion. For instance, in October 2020, Endo International plc acquired BioSpecific Technologies Corp. to expand the portfolio and production of XIAFLEX and QWO to treat Dupuytren's disease.

The expansion of Dupuytren's contractures market is facilitated by the increase in R&D activities and the emergence of new market players. Also, the demand for the treatment is expected to to rise rapidly due to significant unmet medical needs and advancements in medical technology. However, the expensive treatment procedures and the absence of infrastructure in low-income nations limit the industry growth rate.

The market is segmented upon the disease type, type, end user, and region. Due to the presence of key companies and the high prevalence of the condition, North America dominates the global market for Dupuytren's disease. Moreover, increased aged population and the advanced healthcare system are the main factors that are expected to boost the market in the region. Moreover, factors such as favorable reimbursement circumstances, high patient disposable income, and accessibility to cutting-edge treatment options in the region aid in dominating the market. However, Asia Pacific region is anticipated to grow at the fastest rate over the forecast period due to the growing patient base, increasing healthcare spending, and expanding government supports in the region.

Dupuytren’s Disease Market Segmentation

在Dupuytren的disea经营的大公司se market include Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., Actiza Pharmaceutical Private Limited, Endo International plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK plc., AstraZeneca, Hikma Pharmaceuticals PLC, LEO Pharma A/S, Fresenius Kabi AG among others. The industry leaders are involved in campaigns and social activities to spread awareness about the disorder. For instance, in October 2022, Endo International plc featured a series of videos named Coffee & Cords, in which the patients describe their daily struggles with Dupuytren's contracture. The campaign aimed to educate people with signs, symptoms, causes, diagnosis, and treatment of the disease.